<DOC>
	<DOC>NCT01553721</DOC>
	<brief_summary>This is a placebo-controlled, double-blind, phase II clinical study to evaluate the efficacy and safety of Udenafil in patient with Pulmonary Arterial Hypertension(PAH).</brief_summary>
	<brief_title>Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>• Subjects aged 18 and over who have any of the following diseases primary Pulmonary Arterial Hypertension secondary Pulmonary Arterial Hypertension caused by connective tissue disease [Phase IIb] Pulmonary Arterial Hypertension caused by congenital heart disease(including Eisenmenger syndrome) Subjects with pulmonary arterial hypertension caused by any etiology other than those specified in the inclusion criteria BMI(Body Mass Index) &lt; 18.5kg/m2 Subjects with hypotension(SBP/DBP&lt;90/50mmHg) or uncontrolled hypertension(SBP/DBP&gt;170/100mmHg) Creatinine clearance ≤ 30mL/min History of nonarteritic anterior ischemic optic neuropathy(NAION)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>